These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 21732299)

  • 41. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases.
    Troche CJ; Tacke J; Hinzpeter B; Danner M; Lauterbach KW
    Eur Heart J; 1998 Apr; 19 Suppl C():C59-65. PubMed ID: 9597427
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence.
    Ali R; Alexander KP
    Am J Geriatr Pharmacother; 2007 Mar; 5(1):52-63. PubMed ID: 17608248
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Secondary prevention after cardiac infarct; therapeutic efficiency--cost-benefit ratio].
    Kreuzer J; Kübler W
    Internist (Berl); 2001 May; 42(5):713-9. PubMed ID: 11400578
    [No Abstract]   [Full Text] [Related]  

  • 44. [Early treatment of statins after acute coronary syndrome?].
    Hamm CW
    Dtsch Med Wochenschr; 2011 Sep; 136(39):1941. PubMed ID: 21948603
    [No Abstract]   [Full Text] [Related]  

  • 45. Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial.
    Ohsfeldt RL; Gandhi SK; Smolen LJ; Jensen MM; Fox KM; Gold A; Hsia J
    J Med Econ; 2010; 13(3):428-37. PubMed ID: 20662625
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Prognostic implictions of the lack of a lipid-lowering strategy].
    Baessler A; Fischer M; Hubauer U; Stark K; Hengstenberg W; Wiedmann S; Neureuther K; Holmer S; Mayer B; Schunkert H; Hengstenberg C
    MMW Fortschr Med; 2006 Nov; 148(44):38. PubMed ID: 17619439
    [No Abstract]   [Full Text] [Related]  

  • 47. Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
    Tonelli M; Isles C; Curhan GC; Tonkin A; Pfeffer MA; Shepherd J; Sacks FM; Furberg C; Cobbe SM; Simes J; Craven T; West M
    Circulation; 2004 Sep; 110(12):1557-63. PubMed ID: 15364796
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evidence-based use of statins for primary prevention of cardiovascular disease.
    Minder CM; Blaha MJ; Horne A; Michos ED; Kaul S; Blumenthal RS
    Am J Med; 2012 May; 125(5):440-6. PubMed ID: 22387091
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Lower, lower, lower. The LDL goal value of 200 mg/dl is still much too high].
    Einecke D
    MMW Fortschr Med; 2004 Mar; 146(13):4-5. PubMed ID: 15219114
    [No Abstract]   [Full Text] [Related]  

  • 50. Is it appropriate to make statins available over the counter? Over-the-counter statins are worth considering in primary prevention of cardiovascular disease.
    Gotto AM
    Circulation; 2006 Sep; 114(12):1310-4; discussion 1314. PubMed ID: 16982952
    [No Abstract]   [Full Text] [Related]  

  • 51. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.
    Greving JP; Visseren FL; de Wit GA; Algra A
    BMJ; 2011 Mar; 342():d1672. PubMed ID: 21450800
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A trial-based approach to statin guidelines.
    Ridker PM; Wilson PW
    JAMA; 2013 Sep; 310(11):1123-4. PubMed ID: 23942579
    [No Abstract]   [Full Text] [Related]  

  • 53. Study stirs debate about statin use in those without high cholesterol.
    Mayo Clin Womens Healthsource; 2009 Apr; 13(4):3. PubMed ID: 19255535
    [No Abstract]   [Full Text] [Related]  

  • 54. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
    Moyad MA; Merrick GS
    Urol Nurs; 2007 Apr; 27(2):166-8. PubMed ID: 17494461
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cholesterol-lowering and cancer in the prevention of cardiovascular disease.
    Oliver MF
    QJM; 2010 Mar; 103(3):202. PubMed ID: 20083536
    [No Abstract]   [Full Text] [Related]  

  • 56. Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases.
    Corrao G; Scotti L; Zambon A; Baio G; Nicotra F; Conti V; Capri S; Tragni E; Merlino L; Catapano AL; Mancia G
    Atherosclerosis; 2011 Aug; 217(2):479-85. PubMed ID: 21592477
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cholesterol lowering with statins: how WOSCOPS confounded the skeptics.
    Shepherd J
    Atheroscler Suppl; 2007 Aug; 8(2):9-12. PubMed ID: 17586101
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Statins for millions more?
    Lancet; 2014 Feb; 383(9918):669. PubMed ID: 24560042
    [No Abstract]   [Full Text] [Related]  

  • 59. [Benefits and risks for primary prevention with statins in the elderly].
    Joseph JP; Afonso M; Berdaï D; Salles N; Bénard A; Gay B; Bonnet F
    Presse Med; 2015 Dec; 44(12 Pt 1):1219-25. PubMed ID: 26585744
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Statins for people with diabetes.
    Cheung BM
    Lancet; 2008 Jan; 371(9607):94-5. PubMed ID: 18191668
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.